What are Inhibrx Biosciences, Inc.'s total assets?

Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.

How much debt does Inhibrx Biosciences, Inc. have?

Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.

How much cash does Inhibrx Biosciences, Inc. have?

Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.

Can Inhibrx Biosciences, Inc. cover its short-term obligations?

Its current ratio is 6.46 — current assets exceed current liabilities.

Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?

Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Inhibrx Biosciences, Inc. INBX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$161.66M-25.3%	$124.22M-18.6%	$153.09M-22.0%	$186.57M-17.8%	$216.52M-14.2%
Prepaid expenses and other current assets	$31.86M-15.8%	$29.02M-13.5%	$27.96M-34.7%	$30.45M-36.5%	$37.83M—
Total current assets	$171.34M-23.3%	$132.83M—	$161.42M—	$193.96M—	$223.39M—
Property and equipment, net	$3.2M-42.4%	$3.73M—	$4.31M—	$4.89M—	$5.55M—
Accumulated depreciation	$11.66M+21.8%	$11.12M—	$10.58M—	$10.23M—	$9.57M—
Operating lease right-of-use assets	10.2%0.0%	10.2%—	10.2%—	10.2%—	10.2%—
Other non-current assets	$4.38M-35.6%	$4.38M—	$5.74M—	$6.81M—	$6.8M—
Total assets	$183.97M-24.2%	$146.48M—	$177.47M—	$212.12M—	$242.64M—
Accounts payable	$29.77M-31.6%	$29.9M-22.7%	$33.2M-17.8%	$38.8M+46.8%	$43.53M—
Accrued expenses	$2.24M-17.5%	$7.45M—	$4.84M—	$3.85M—	$2.72M—
Operating lease liabilities, current	$2.41M+22.0%	$2.33M—	$2.25M—	$2.17M—	$1.97M—
Total current liabilities	$26.51M-39.2%	$33.8M—	$35.98M—	$38.94M—	$43.64M—
Long-term debt	$174.99M+77.4%	$100.56M—	$99.92M—	$99.28M—	$98.65M—
Operating lease liabilities, non-current	$3.5M-40.8%	$4.13M—	$4.74M—	$5.34M—	$5.9M—
Operating Lease Liabilities (Total)	$5.9M-25.0%	$6.45M—	$6.99M—	$7.51M—	$7.88M—
Total liabilities	$205M+38.3%	$138.49M—	$140.64M—	$143.56M—	$148.2M—
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	120M0.0%	120M—	120M—	120M—	120M—
Additional paid-in capital	$258.59M+6.0%	$254.18M—	$250.18M—	$246.66M—	$243.89M—
Retained earnings	-$279.63M-87.1%	-$246.19M—	-$213.35M—	-$178.1M—	-$149.44M—
Total stockholders' equity	-$21.04M-122%	$7.99M-94.0%	$36.83M-79.4%	$68.56M-68.7%	$94.44M+716%
Total liabilities and stockholders' equity	$183.97M-24.2%	$146.48M—	$177.47M—	$212.12M—	$242.64M—
Other current assets	$262K-2.6%	$238K—	$410K—	$283K—	$269K—
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$186K—	——	——	——	——
Other Receivables	$186K—	——	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$4.38M-35.6%	$4.38M—	$5.74M—	$6.81M—	$6.8M—
Net Investment in Lease	$5.05M-26.8%	$5.54M—	$6M—	$6.46M—	$6.9M—
Operating lease right-of-use assets	$5.05M-26.8%	$5.54M—	$6M—	$6.46M—	$6.9M—
Other non-current assets	$4.38M-35.6%	$4.38M—	$5.74M—	$6.81M—	$6.8M—
Property, plant and equipment at cost	$14.85M-1.7%	$14.85M—	$14.88M—	$15.11M—	$15.11M—
Operating Lease Right-of-Use Assets in Other Assets	$5.05M-26.8%	$5.54M—	$6M—	$6.46M—	$6.9M—
Software and Technology Licenses, Net	$4.38M-35.6%	$4.38M—	$5.74M—	$6.81M—	$6.8M—
Accrued Manufacturing Costs	$2.24M-17.5%	$7.45M—	$4.84M—	$3.85M—	$2.72M—
Other Commercial Liabilities	$15.34M-53.2%	$25.53M—	$26.96M—	$28.48M—	$32.77M—
Accrued Liabilities, Current	$15.34M-53.2%	$25.53M—	$26.96M—	$28.48M—	$32.77M—
Compensation and benefits	$2.24M-17.5%	$7.45M—	$4.84M—	$3.85M—	$2.72M—
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Professional Service Fees Payable	$591K-3.7%	$447K—	$598K—	$1.07M—	$614K—
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Total debt	$180.9M+69.8%	$107.01M—	$106.91M—	$106.79M—	$106.53M—
Common Stock Par Value Per Share	$0.000.0%	$0.00—	$0.00—	$0.00—	$0.00—
Common Stock Shares Issued	14.6M+0.9%	14.6M—	14.5M—	14.5M—	14.5M—
Convertible Preferred Stock Authorized Shares	15M0.0%	15M—	15M—	15M—	15M—
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1K0.0%	$1K—	$1K—	$1K—	$1K—
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.00—	$0.00—	$0.00—	$0.00—
Shares Reserved for Future Issuance Under Stock Plans	5M-2.1%	5.1M—	5.1M—	5.1M—	5.1M—
Cumulative Cost Basis	$14.85M-1.7%	$14.85M—	$14.88M—	$15.11M—	$15.11M—
Clinical drug substance and product manufacturing	$2.14M-75.3%	$5.54M—	$5.91M—	$8.44M—	$8.68M—
Clinical trials	$8.58M-54.6%	$10.79M—	$14.2M—	$13.13M—	$18.9M—
Interest expense	——	——	——	——	$857K—
Other outside research and development	$236K-62.1%	$111K—	$286K—	$771K—	$622K—
Professional service fees	$591K-3.7%	$447K—	$598K—	$1.07M—	$614K—
Clinical drug substance and product manufacturing	$1.56M-17.6%	$1.88M—	$2.25M—	$2.48M—	$1.89M—
Clinical trials	$5.79M+300%	$4.57M—	$2.82M—	$1.68M—	$1.45M—
Common stock, capital shares reserved for future issuance	$5.02M-2.1%	$5.13M—	$5.11M—	$5.13M—	$5.13M—
Common stock, par value (in dollars per share)	$00.0%	$0—	$0—	$0—	$0—
Common stock, shares authorized (in shares)	$120M0.0%	$120M—	$120M—	$120M—	$120M—
Common stock, shares issued (in shares)	$14.61M+0.9%	$14.58M—	$14.5M—	$14.48M—	$14.48M—
Common Stock, Shares, Outstanding	$14.61M+0.9%	$14.58M—	$14.5M—	$14.48M—	$14.48M—
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.10.0%	$0.1—	$0.1—	$0.1—	$0.1—
Other accrued liabilities	$693K+82.4%	$328K—	$300K—	$387K—	$380K—
Outside research and development services	$506K-58.6%	$448K—	$736K—	$766K—	$1.22M—
Preferred Stock, Par or Stated Value Per Share	$00.0%	$0—	$0—	$0—	$0—
Preferred Stock, Shares Authorized	$15M0.0%	$15M—	$15M—	$15M—	$15M—
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Software licenses	$1.39M—	$1.3M—	$1.29M—	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Inhibrx Biosciences, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Inhibrx Biosciences, Inc.'s total assets?: Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.
How much debt does Inhibrx Biosciences, Inc. have?: Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.
How much cash does Inhibrx Biosciences, Inc. have?: Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.
Can Inhibrx Biosciences, Inc. cover its short-term obligations?: Its current ratio is 6.46 — current assets exceed current liabilities.
Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?: Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.